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Introduction 
Duchenne (OMIM 310200) and its less severe allelic form Becker (OMIM 300376) 
muscular dystrophy (DMD/ BMD) are common x-linked recessive hereditary 
neuromuscular diseases. These disorders result from heterogeneous mutations in 
the dystrophin gene (1-2). The incidence of DMD is 1 in 3500 and BMD is 1 in 
18000 male births (3-4). The dystrophin gene that spans a distance of more than 2.5 
million base pairs is located at the Xp21 locus and is the largest human gene, which 
consists of 79 exons. Sequencing this huge gene is time-consuming and, fortunately, 
the deletions in this gene are non-randomly distributed with many of the large gene 
deletions that occur in the dystrophin gene can be detected in specific hotspot areas 
of the gene. These hotspots are clustered in two main regions: 1. about 20% at the 5’ 
proximal portion of the gene (exons 1,3,4,5,8,13,19); and 2. 80% at the mid-distal 
region i.e. 42–45, 47, 48, 50–53 (5-6).
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frequent deleted exons were exon 50 (15 %) and exon 49 (14%). No deletion 
was detected in exon 3.
Conclusion
This study suggests that the frequency and pattern of dystrophin gene deletions 
in DMD/ BMD in the Azeri Turk population of North West Iran occur in the 
same pattern when compared with other ethnic groups.
Keywords: Dystrophin; Multiplex PCR; Duchenne Muscular Dystrophy; 
Becker Muscular Dystrophy
ORIGINAL ARTICLE
43Iran J Child Neurol. 2015 Winter Vol 9 No 1
Exon Deletion Pattern in Duchene Muscular Dystrophy in North West of Iran
The reading frame rule explains the clinical differences 
between DMD/ BMD at the molecular level with the 
deletions that cause shifts in the reading frame of the 
dystrophin mRNA (out-of-frame) that lead to no or very 
low production of functional dystrophin resulting in 
more severe DMD phenotype whereas the milder BMD 
phenotype occurs if the reading frame is preserved (in-
frame) and semi functional proteins are produced (7). In 
about 65% of DMD cases, the mutation of the dystrophin 
gene are large-scale gene deletions, in approximately 
5% are duplications and in 30% are point mutations (8-
10). Due to no effective treatment available for DMD/ 
BMD at present, an accurate genetic diagnosis may offer 
prenatal diagnosis for familial DMD/ BMD although 
about 30% of cases are the result of new mutations (11).
The frequency and distribution of dystrophin gene 
deletions in DMD and BMD patients show that there 
are different patterns among different populations. In a 
previous study of authors in East Azerbaijan Province, 
in 46 male patients with clinical suspicion of DMD/ 
BMD, 21 (46%) had deletions.
This study investigates the rate, types, and distributions 
of deletions in DMD/ BDM patients (with a relatively 
large sample) in the Azeri Turk population of North 
West Iran by using multiplex polymerase chain reaction 
(MPCR) assays. 
Materials & Methods
All patients were evaluated by an expert pediatric 
neurologist during 2004–2013. Clinical diagnosis 
in 104 patients was made by using standard clinical 
diagnosis criteria for DMD/ BMD in conjunction with 
high serum levels of Creatine Phosphokinase (CPK) at 
least 10 times the upper limit of normal and compatible 
electromyographic results (12). In 6 patients, the 
diagnosis was confirmed by a muscle biopsy.
All patients were of Azeri Turk origin (or from North 
West Iran). Patients (or their parents) were informed 
about the study and written consent was signed by either 
the patient or the parents for blood sampling. This study 
was approved by Tabriz University of Medical Sciences 
Ethical Committee. Genomic DNA was extracted from 
peripheral blood leukocytes using standard protocols.
For molecular genetic studies, MPCR assays were done 
using three complementary MPCR assays that detected 
26 exons of the dystrophin gene (6). Three separate PCR 
assays were performed on each patient’s DNA sample to 
amplify 26 dystrophin gene exons (13). The following 
exons were studied during this protocol: exon number: 
3, 4, 6 , 8, 12, 13, 16, 17, 19, 32, 34, 41, 42 , 43, 44, 45, 
46, 47, 48, 49, 50, 51, 52, and 60; and the promoter zone.
Results
Each patient’s DNA sample was checked alongside a 
normal sample for 24 exon-deletion (Fig. 1)
In this study, deletions were detected in 63 (57.3%) 
patients, among these 21 patients (33.3%) had single 
exon deletions and 42 patients (66.7%) had more than 
one deletion (range 2–8): 20 patients (31.7%) had 
two deletions, 4 patients (6.3%) had three deletions, 6 
patients (9.5%) had four deletions, 4 patients (6.3%) had 
five deletions, 1 patient (1.6%) six deletions, 3 patients 
(4.8%) had seven deletions, and the remaining 4 patients 
(6.3%) had 8 exon deletions. The most frequently 
deleted exons were exon 50 (15%) and exon 49 (14%). 
No deletion was detected on exon 3. Approximately 
83% of all deletions were located on exons 42–52 mid-
distal hot spot (Fig. 2).
In this study, patients with Becker totaled 6, and 
considering the diversity of distribution for gene 
deletions in these patients. Because of the small sample 
size, statistical analysis to determine genotype and 
phenotype correlations was impossible.
Discussion
Duchenne and Becker muscular dystrophy are common 
inherited recessive x-linked motor diseases. Mapping 
and molecular genetic studies have indicated that both 
are the result of mutations in the huge gene that encodes 
dystrophin. There are various laboratory techniques to 
assess deletion of the dystrophin gene. Some studies 
have used the Southern Blot technique for this purpose, 
which is difficult and time consuming. Nevertheless, it 
has applications in identifying deletion and duplication 
of the whole gene, locating the origin of deletions and 
duplications to determine the effect of mutation on 
the reading frame, and, ultimately, to find the exon 
junctions. A Southern blot permits prognostication of 
severity by distinguishing in-frame versus frameshift 
mutations in over 90% of cases. Some studies have 
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However, the population of the Philippines shows that 
most deletions are at the beginning of the gene. The same 
results are reported from other countries as well (18-20). 
In this respect, a few studies have been conducted in 
Iran, including a study by Akbari et al. on 100 patients 
with Duchenne and Becker dystrophy with 52 patients 
(52%) showed deletion, 81% of deletions were at the 
end (exons 44–55), and 19% at the first hotspot of gene 
(exons 2–19). The majority of deletions were identified 
in exons 47, 48, and 46 (18-21). 
In Galehdari et al. reported that in Ahwaz 17 patients 
with suspected Duchenne gene deletion was present 
in 53% of patients, all of which were in exons 44–51 
(19-22). In a previous study, 46 boy patients in East 
Azerbaijan Province showed that 21 patients (46%) had 
deletions. The majority of deletions were observed in 
exons 45, 49, and 50 at a frequency of 14.3%. These 
exons were present as the most mutationable exons in 
patients in this province (20-23).
 In our study, the rate and distribution of deletions in 
patients was similar to the deletion pattern in previous 
studies in Iran and in terms of pattern of deletion and 
distribution Iran and Turkey are similar (21-24).
The difference in distribution of deletions can be 
explained by inclusion criteria for diagnosis of cases, 
for example: biopsy confirmed or clinical suspicion, 
different methods used for genetic examination i.e. 
MLPA technique, or cDNA, Southern Blot or multiple 
PCR or combination of them; and number of exons 
studied in MPCR. Finally, the variations strongly suggest 
that sequence differences exist in the introns and that 
the differences are in agreement with genetic distances 
among populations. The similarities further suggest that 
some intronic sequences have been conserved and that 
those will trigger recurrent deletions (22-25).
In this study, there were 6 patients with Becker, and 
considering the diversity of the distribution of gene 
deletion in these patients, and because of the small 
sample size, statistical analysis was impossible. 
However, the results of various studies have shown that 
based on gene deletion patterns, the disease phenotype 
cannot be determined (23-27).
Among the applied objectives of this study was to enable 
research groups and patients to participate in new clinical 
trials through the identification of gene deletion patterns 
used MPCR, which are cheaper, faster, and easier than 
Southern Blot; and because of its high speed, it is ideal 
for prenatal diagnosis. However, it can only allow for 
the identification of deletions. Therefore, it is advised to 
concurrently run both tests. Another method is the use 
of quantitative PCR (QPCR) to determine gene dosage. 
This method has an important application in determining 
carriers, but deleted or duplicated exons should first be 
identified (14-16).
The Multiplex Ligation-dependent Probe Amplification 
(MLPA) technique allows for the possibility to assess 
all deletions or duplications of the dystrophin gene. Lai 
et al. compared MPCR and MLPA and concluded that 
MLPA detected all known deletions and duplications 
as well as the extent and distribution of the deletions 
and duplications, which in turn facilitated a genotype-
phenotype correlation (17).
According to this study, using MPCR in Azeri Turk 
patients in North West Iran, showed that intragenic 
deletions were detected in 63 (57.3%) DMD/ BMD 
patients.
There are various reports on the frequency and pattern of 
intragenic deletions in different populations. According 
to these reports, in addition to deletion frequency 
differences in different populations, the distribution of 
deletions in the dystrophin gene is different. Table 1 
presents a summary of rate and distribution patterns of 
deletion for different countries available in the Leiden 
Muscular Dystrophy database (http://www.dmd.nl/
DMD_deldup.html).
Table 1 shows that in North America and Europe, the 
deletion rates vary from 42% to 90%, deletion rates in 
Asian countries vary from 31% to 86%, and the deletion 
in Latin American countries varied from 47% to 93%. 
The deletion rate in Africa was reported at 51%. 
In this study, 83% of deletions were in the mid-distal 
hotspot of the gene (exons 44–52) and 17% in the 5’ 
proximal portion of the gene (exons 4–22). The highest 
frequency of deletion was observed in exon 50 (15%), 
then followed by exon 49 (14%).
Table1 shows that European countries varied between 
70–80% of deletions and are located in central areas of 
dystrophin gene (exons 44–52). In North America, 45–
70% of deletions are in the central area. In most Asian 
countries, deletions are in the center area of gene as well. 
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Fig. 1. Each sample was studied for 24 exons to detect possible exon deletion. Line 1: Marker- Line 





































result in a clinical phenotype like BMD. This AON can 
be applied to about 13% on the DMD patients. (28-30).
In conclusion, the present study suggests that the 
frequency and pattern of dystrophin gene deletions in 
DMD/ BMD in the Azeri Turk population in North West 
Iran occur with the same pattern compared with other 
ethnic groups.
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and based on these indicators and genetic mutations. 
Researchers are working on exon skipping as a method 
to introduce novel dystrophin production and turn severe 
DMD into BMD type disease (i.e. a milder form). As 
mentioned earlier, DMD is caused by mutations in the 
DMD gene, mostly the deletion of one or more of the 79 
exons in the dystrophin gene. These mutations disturb the 
synthesis of the dystrophin protein. The specific skipping 
of one or more exons flanking the specific deletion in 
DMD patients allows the introduction of BMD-like 
dystrophin and as a result, converts severe DMD into 
a typically milder BMD. The exon-skipping approach 
is mutation specific. Therefore, each mutation needs a 
separate exon to be skipped and compound to induce it. 
Currently, new therapeutic strategies, such as antisense-
mediated exon skipping, are in early phase of clinical 
trials and have the potential to change the course of the 
DMD disease dramatically. In one study, intramuscular 
injection of an antisense oligonucleotide (AON) 
induced skipping of exon 51 and restored the disrupted 
open reading frame and, therefore, the production of 
dystrophin in 4 DMD patients with deletion of exons 
48–50, 49–50, 50, and 52, respectively. Clinical trials 
with systemic administration of AON are taking place, 
and, if successful, therapeutic skipping using an AON 
that targets exon 51 can stop further muscle wasting to 
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Fig 1. Each sample was studied for 24 exons to detect possible exon deletion. Line 1: Marker- Line 
2: Normal sample- Line 3: Sample from DMD patient showing deletion in exon 51
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Fig 2. Distribution of gene deletion in 24 exons in patients with DMD/ BMD in North West Iran 
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